What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cancer
Surgery, Thrombosis, Anesthesia, Venous thrombosis and Cancer are his primary areas of study.
His studies in Thrombosis integrate themes in fields like Thrombolysis, Fibrinolysis, Embolism and Ultrasound.
He works mostly in the field of Fibrinolysis, limiting it down to topics relating to Ultrasonic sensor and, in certain cases, Fibrin, as a part of the same area of interest.
His Anesthesia research incorporates elements of Ximelagatran, Direct thrombin inhibitor and Warfarin.
His Venous thrombosis research incorporates themes from Complication and Vein.
His biological study spans a wide range of topics, including Venous thromboembolism and Intensive care medicine.
His most cited work include:
- Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (1849 citations)
- Development and validation of a predictive model for chemotherapy-associated thrombosis (1114 citations)
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014 (1069 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Surgery, Thrombosis, Fibrin and Fibrinogen.
His Internal medicine study incorporates themes from Endocrinology and Cardiology.
His research investigates the link between Surgery and topics such as Warfarin that cross with problems in Prothrombin time.
In his work, Anticoagulant is strongly intertwined with Anesthesia, which is a subfield of Thrombosis.
His Fibrin research is multidisciplinary, incorporating elements of Plasmin, Biochemistry, Molecular biology, Fibrinolysis and Thrombin.
His Fibrinogen research includes themes of Endothelial stem cell, Gel electrophoresis, Fibrin Monomer and Fibroblast growth factor.
He most often published in these fields:
- Internal medicine (28.20%)
- Surgery (24.71%)
- Thrombosis (21.51%)
What were the highlights of his more recent work (between 2008-2021)?
- Internal medicine (28.20%)
- Surgery (24.71%)
- Cancer (11.34%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Surgery, Cancer, Platelet and Venous thromboembolism.
His Internal medicine research is multidisciplinary, incorporating perspectives in Endocrinology and Cardiology.
Charles W. Francis combines subjects such as Dosing, Warfarin and Antithrombotic with his study of Surgery.
His Cancer research integrates issues from Intensive care medicine, Ambulatory, Asymptomatic, Thrombosis and Prospective cohort study.
Charles W. Francis studied Platelet and ABO blood group system that intersect with Antibody.
His Pulmonary embolism study combines topics from a wide range of disciplines, such as Inferior vena cava, Vitamin K antagonist and Fondaparinux.
Between 2008 and 2021, his most popular works were:
- Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (1849 citations)
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014 (1069 citations)
- Prevention of VTE in Orthopedic Surgery Patients (1000 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Cancer
His primary areas of investigation include Surgery, Cancer, Venous thromboembolism, Internal medicine and Intensive care medicine.
His research in Surgery intersects with topics in Dabigatran and Antithrombotic.
His Venous thromboembolism research is under the purview of Thrombosis.
The Thrombosis study combines topics in areas such as Platelet, Platelet transfusion and Heparin.
Charles W. Francis has included themes like Venous thrombosis and MEDLINE in his Intensive care medicine study.
The various areas that Charles W. Francis examines in his Pulmonary embolism study include Apixaban, Rivaroxaban, Fondaparinux, Inferior vena cava and Vitamin K antagonist.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
